INTI · Inhibitor Therapeutics, Inc.
$0.09
At close · Aug 27
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been fully executed and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not currently alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$15.47M
Shares
173.79M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Francis E. O'Donnell, Jr. | Executive Chairman and Chief Executive Officer | $1,118,630 |
| James A. McNulty | Interim Chief Financial Officer, Secretary and Treasurer | $362,574 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Francis E. O'Donnell, Jr. | Executive Chairman and Chief Executive Officer | $1,137,886 |
| James A. McNulty | Interim Chief Financial Officer, Secretary and Treasurer | $359,756 |